Αρχική World News FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC World News FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC Από Ogkologos - 27 Νοεμβρίου, 2025 395 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Experimental CAR T-Cell Therapy Shrinks Tumors in Children with Deadly Brain... 2 Ιανουαρίου, 2025 Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... 18 Ιουνίου, 2021 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... 7 Ιουλίου, 2021 EMA Recommends Extension of Therapeutic Indications for Cabozantinib 29 Απριλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Your questions on our research strategy FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated... Changes in Metabolism Help Melanomas Spread 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with...